Image

Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4

Recruiting
18 years of age
Both
Phase 1/2

Powered by AI

Overview

Primary Objectives

  • Determine the biodistribution of [18F]-C-SNAT4 in 5 healthy volunteers. Secondary Objectives
  • Determine the dosimetry of [18F]-C-SNAT4 PET in healthy volunteers and patients with lung cancer.
  • Determine the acute toxicity of [18F]-C-SNAT4 PET in healthy volunteers and patients with lung cancer.
  • Determine whether uptake in [18F]-C-SNAT4 PET imaging is significantly different in tumor and corresponding contralateral noncancer tissue in patients with lung cancer (tested by Wilcoxon test) before the therapy.
  • Determine/verify the safety profile of the [18F]-C-SNAT4 radiotracer, as an imaging agent in patients with lung cancer.
  • Determine the time of maximal [18F]-C-SNAT4 radiotracer uptake post injection.

Eligibility

Inclusion Criteria:

  • ANC ≥ 1.5 x 109/L without myeloid growth factor support for 7 days preceding lab assessment
  • Hgb ≥ 9 g/dL (90 g/L); < 9 g/dL (< 90 g/L) is acceptable if Hgb corrected to ≥ 9 g/dL (90 g/L) as by growth factor or transfusion prior to PET scan
  • Platelet count ≥ 100 x 109/L w/o blood transfusions for 7 days preceding lab assessment
  • Bilirubin ≤ 1.5 x upper limit of normal (ULN) except for pts with documented history of Gilbert's disease
  • ALT ≤ 2.5 x ULN
  • AST ≤ 2.5 x ULN
  • Alkaline phosphatase (AP) ≤ 3 x ULN
  • If a women of childbearing potential (WCBP): negative early pregnancy test (EPT)
  • Karnofsky Performance Status (KPS) ≥ 60
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Has already begun non-surgical therapy for any recurrence, prior to the first [18F]-C-SNAT4 PET/CT scan
  • Severe/uncontrolled inter-current illness within the previous 28 days prior to PET scan.
  • Any other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation.
  • History of allergic reactions to IV contrasts or reactions attributed to compounds of similar chemical or biological composition to [18F]-C-SNAT4 used in study.
  • Pregnant or nursing
  • Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot fit through the PET/CT bore (diameter 70 cm).

Study details

Cancer, Lung Cancer

NCT04017819

Stanford University

29 April 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.